Investigational Drug Information for Apricitabine
✉ Email this page to a colleague
What is the development status for investigational drug Apricitabine?
Apricitabine is an investigational drug.
There have been 6 clinical trials for Apricitabine.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2008.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Communicable Diseases. The leading clinical trial sponsors are Avexa and [disabled in preview].
Summary for Apricitabine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 826 |
| WIPO Patent Applications | 495 |
| Japanese Patent Applications | 248 |
| Clinical Trial Progress | Phase 2 (2008-05-01) |
| Vendors | 45 |
Recent Clinical Trials for Apricitabine
| Title | Sponsor | Phase |
|---|---|---|
| A Long Term Safety Study of Apricitabine in HIV-infected Patients | Avexa | Phase 3 |
| Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection | Avexa | Phase 2/Phase 3 |
| A Long Term, Safety Study of Apricitabine in HIV-infected Subjects | Avexa | Phase 2 |
Clinical Trial Summary for Apricitabine
Top disease conditions for Apricitabine
Top clinical trial sponsors for Apricitabine
US Patents for Apricitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
